BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260602T080000
DTEND;TZID=America/New_York:20260602T093000
DTSTAMP:20260613T005430
CREATED:20260512T135746Z
LAST-MODIFIED:20260602T123310Z
UID:3043-1780387200-1780392600@lifescievents.com
SUMMARY:NextCure Virtual KOL Event to Discuss the ASCO 2026 Presentation of Dose Escalation Data from NXTC’s Phase 1 Trial of SIM0505 for the Treatment of Gynecologic Cancers including Ovarian Cancer and Uterine Serous Carcinoma
DESCRIPTION:Join NextCure for a virtual key opinion leader (KOL) event featuring Ursula Matulonis\, MD (NextCure Scientific Advisory Board and Dana Farber Cancer Institute)\, Rakesh Dixit\, PhD\, DABT (NextCure Scientific Advisory Board)\, and Beryl Manning-Geist\, MD (Emory University)\, who will join Company management to discuss first reported clinical efficacy data from NextCure’s Phase 1 dose escalation study of SIM0505\, presented as a poster on June 1st at the 2026 American Society for Clinical Oncology Annual Meeting (ASCO 2026). \nThe event will focus on the unmet need in platinum-resistant ovarian cancer (PROC) and uterine serous carcinoma (USC)\, two gynecologic malignancies where effective treatment options remain limited. The program will also cover the science behind SIM0505\, an investigational antibody-drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload\, and the biological rationale for CDH6 as a therapeutic target in these tumors. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/gkso204j/.
URL:https://lifescievents.com/event/gkso204j/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/05/NextCure-Banner.png
END:VEVENT
END:VCALENDAR